期刊文献+

补元养心汤对扩张型心肌病心肾功能不全的临床疗效研究 被引量:3

Clinical Effect of Buyuan Yangxin Tang on Heart and Kidney Insufficiency of Dilated Cardiomyopathy
下载PDF
导出
摘要 目的:探讨补元养心汤对扩张型心肌病心肾功能不全的治疗效果。方法:选取我科扩张型心肌病心力衰竭合并肾功能不全患者200例,随机分为实验组和对照组,对照组按心力衰竭指南给予西药常规治疗,实验组在西药常规治疗的基础上加用我院自拟方"补元养心汤"。4周为1疗程,均治疗1个疗程。对比治疗前后两组患者的临床疗效评分及左室舒张末期内径(LVDd)、左室射血分数(LVEF)、心胸比率、脑钠素(BNP)、CRP、血肌酐、尿素氮、尿酸等指标,观察补元养心汤的治疗效果。结果:(1)治疗前后,实验组总有效率为96.0%,对照组总有效率为71.4%,实验组优于对照组(P<0.05);(2)与治疗前比较,两组心脏指标明显改善,LVEF不同程度提高(P对照组<0.05,P实验组<0.01),LVDd和BNP有所下降(P对照组<0.05,P实验组<0.01);心胸比缩小(P对照组<0.05,P实验组<0.01);CRP有明显的改善(P对照组<0.05,P实验组<0.01);与对照组比较,实验组各项心功能指标改善更显著(P<0.05);(3)与治疗前比较,两组肾脏指标均改善,血肌酐、尿素氮、血尿酸均较治疗前下降(P对照组<0.05,P实验组<0.01),组间比较,实验组各项肾功能指标改善更明显(P<0.05)。结论:在西医治疗的基础上加用补元养心汤可在改善患者临床症状和心功能的同时,改善肾脏指标,弥补了西药治疗心衰中对肾脏的损害。 Objective: to explore the curative effect of Buyuan Yangxin Tang on the heart and kidney insufficiency of dilated cardiomyopathy. Methods: 200 patients with dilated cardiomyopathy-induced heart failure combined with kidney insufficiency from our department were randomly divided into experimental group( EG) and control group( CG). CG were given western conventional therapy under the guidance of heart failure while EG were added with our self-made Buyuan Yangxin Tang,for four weeks as a course. Compare the curative effect scores before and after treatment,and other indexes like LVDd,LVEF,cardio-thoracic ration,BNP,CRP,serum creatinine,urea nitrogen and uric acid,to observe the therapeutic effect of Buyuan Yangxin tang. Results:( 1) before and after therapy,the total effective rate of EG was 96%,CG 71. 4%,the former superior to the latter( P 0. 05);( 2) compared to pretherapy,both indexes of the heart improved greatly,LVEF increased to some degree( PCG 0. 05; PEG 0. 01); LVDd and BNP decreased( PCG 0. 05; PEG 0. 01); cardio-thoracic ration decreased( PCG 0. 05; PEG 0. 01); CRP improved significantly( PCG 0. 05; PEG 0. 01); compared to CG,the heart functional index improved more significantly( P 0. 05);( 3)compared to pretherapy,kidney indexes of both group were improved,serum creatinine,urea nitrogen and blood uric acid decreased( PCG 0. 05; PEG 0. 01); EG improved more significantly than CG in all indexes( P 0. 05). Conclusion: western therapy together with Buyuan Yangxin Tang can improve not only clinical symptoms and heart function,but also kidney index,which makes up for the damage to the kidney during treatment of heart failure with western medicine.
出处 《河北中医药学报》 2015年第1期8-11,共4页 Journal of Hebei Traditional Chinese Medicine and Pharmacology
基金 河北省中医药管理局资助项目:No 2012171
关键词 心肌病 心力衰竭 肾功能不全 心肾综合征 补元养心汤 心气虚 肾阳虚 瘀血 水湿 cardiomyopathy heart failure kidney insufficiency heart-kidney syndrome Buyuan Yangxin Tang heart-qi deficiency kidney-yang deficiency static blood water dampness
  • 相关文献

参考文献10

  • 1陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 2心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35(1):5-16. 被引量:554
  • 3JAMESON J N, KASPER D L, HARRISON T R, et al. Harrison's principles of internal medicine [ M ] . 16thed. New York: McGraw - Hill Medical Publishing Di -vision, 2005. ISBN 0 -07 - 140235 -7.
  • 4中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.98-99
  • 5BoerrigterGC, Bumett JC. Cardiorenal syndrome in deeom - pen- sated heart failure: prognostic and therapeutic implica - tions [J] . CurrHeartFailRep, 2004, 1 (3) : 113.
  • 6Neumann J, LigtenbergG, Klein II, eta. t Sympathetic hy - perae- tivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment [J] . Kidney Int, 2004, 65 (5) : 1 568.
  • 7Rosner MH, Roneo C, Okusa MD. The role of inflammation in the cardio -renal syndrome: a focus on cytokines and inflammato- ry mediators [J] . Semin Nephrol, 2012, 32 (1) : 70 -78.
  • 8PIMENTA J M, ALMEIDA R, ARAUJO J P , et al. Amino termi- nal B- type natriuretic peptide, renal func- tion, and prognosis in acute heart failure: A hospital cohort study [ J ] . J Cardiac Fail, 2007, 13:275 -280.
  • 9Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome [J] . Circulation, 2004, 110 (12) : 1 514-1 517.
  • 10夏惠英.温阳活血利水方治疗心力衰竭利尿剂抵抗30例[J].中西医结合心脑血管病杂志,2005,3(10):920-920. 被引量:18

二级参考文献70

  • 1王志民,邹玉宝,宋雷,马爱群,刘唐威,谷惠敏,卢赛兰,武鹏翥,孙兆明,何国宝,张卫,张颖,沈丽,蔡玉岭,甄一松,刘延玲,惠汝太.超声心动图检查调查8080例成人肥厚型心肌病患病率[J].中华心血管病杂志,2004,32(12):1090-1094. 被引量:60
  • 2张寄南,曹克将.肥厚型心肌病诊断与治疗——美国心脏病学学会/欧洲心脏病学学会、美国心脏病协会专家共识导读[J].中华心血管病杂志,2005,33(6):491-494. 被引量:35
  • 3廖玉华,袁璟.扩张型心肌病分子免疫治疗靶点的研究进展[J].中华医学杂志,2006,86(17):1158-1160. 被引量:8
  • 4陈灏珠.实用内科学[M](第11版)[M].北京:人民卫生出版社,2001.10.
  • 5胡大一 吴彦.心衰诊治问答[M].北京:人民卫生出版社,2003.82.
  • 6Richardson P,McKenna W,Bristow M,et al.Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.Circulation,1996,93(5):841-842.
  • 7Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.Circulation,2006,113(14):1807-1816.
  • 8Elliott PM,Mckenna WJ.Natural history of hypertrophic cardiomyopathy.[EB/OL][2006-8-2].http://www.utdol.com/utd/content/topic.do?topicKey=myoperic/11502&type=A&selectedTitle=4~58.
  • 9Cooper LT.Definition and classification of the cardiomyopathies.[EB/OL][2006-8-2].http://www.utdol.com.beckerproxy.wustl.edu/applica.../6085&type=A&selectedTitle=2~5.
  • 10McKenna WJ.Genetics of hypertrophic cardiomyopathy.[EB/OL][2006-8-2].http://www.utdol.com/utd/content/topic.do?topicKey=myoperic/9673&type=A&selectedTitle=3~58.

共引文献1745

同被引文献61

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部